The gene therapy Zolgensma helped children born with a fatal disease grow up to run and play.
But the cost was stunning: $2M per dose.
While taxpayers and charities funded the drug’s early development, execs, venture-capital backers and a pharma giant have reaped the profits.
(Pub. Feb. 2025)
Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices ref...
